Enoxaparin (Lovenox) is described as which type of anticoagulant with outpatient therapy potential?

Enoxaparin (Lovenox) is described as which type of anticoagulant with outpatient therapy potential?

• A. Low molecular weight heparin
• B. Direct oral anticoagulant
• C. Vitamin K antagonist
• D. Thrombolytic agent

Answer: (A)

Enoxaparin is a low molecular weight heparin. It works by boosting antithrombin III, primarily inhibiting factor Xa with some activity against thrombin, leading to anticoagulation. The smaller, more predictable molecules of LMWH give a steadier dose-response and can be given subcutaneously once or twice daily without routine lab monitoring, which makes outpatient therapy feasible. This contrasts with unfractionated heparin, which requires IV infusion and monitoring, and with direct oral anticoagulants or vitamin K antagonists, which are either taken orally or require INR monitoring respectively. It is not a thrombolytic agent, which would actively dissolve clots rather than prevent their formation.

Enoxaparin is a low molecular weight heparin. It works by boosting antithrombin III, primarily inhibiting factor Xa with some activity against thrombin, leading to anticoagulation. The smaller, more predictable molecules of LMWH give a steadier dose-response and can be given subcutaneously once or twice daily without routine lab monitoring, which makes outpatient therapy feasible. This contrasts with unfractionated heparin, which requires IV infusion and monitoring, and with direct oral anticoagulants or vitamin K antagonists, which are either taken orally or require INR monitoring respectively. It is not a thrombolytic agent, which would actively dissolve clots rather than prevent their formation.